JP7465868B2 - 新規化合物 - Google Patents

新規化合物 Download PDF

Info

Publication number
JP7465868B2
JP7465868B2 JP2021521058A JP2021521058A JP7465868B2 JP 7465868 B2 JP7465868 B2 JP 7465868B2 JP 2021521058 A JP2021521058 A JP 2021521058A JP 2021521058 A JP2021521058 A JP 2021521058A JP 7465868 B2 JP7465868 B2 JP 7465868B2
Authority
JP
Japan
Prior art keywords
benzofuran
dione
imidazolidine
disorders
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021521058A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505143A (ja
JP2022505143A5 (cg-RX-API-DMAC7.html
Inventor
アルバロ ジュセッペ
マラスコ アゴスティーノ
Original Assignee
アウトイフオンイ トヘラペウトイクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アウトイフオンイ トヘラペウトイクス リミテッド filed Critical アウトイフオンイ トヘラペウトイクス リミテッド
Publication of JP2022505143A publication Critical patent/JP2022505143A/ja
Publication of JP2022505143A5 publication Critical patent/JP2022505143A5/ja
Application granted granted Critical
Publication of JP7465868B2 publication Critical patent/JP7465868B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2021521058A 2018-10-16 2019-10-16 新規化合物 Active JP7465868B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18200626 2018-10-16
EP18200626.2 2018-10-16
PCT/GB2019/052937 WO2020079422A1 (en) 2018-10-16 2019-10-16 Novel compounds

Publications (3)

Publication Number Publication Date
JP2022505143A JP2022505143A (ja) 2022-01-14
JP2022505143A5 JP2022505143A5 (cg-RX-API-DMAC7.html) 2022-10-25
JP7465868B2 true JP7465868B2 (ja) 2024-04-11

Family

ID=63878368

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021521058A Active JP7465868B2 (ja) 2018-10-16 2019-10-16 新規化合物

Country Status (21)

Country Link
US (1) US20250304564A1 (cg-RX-API-DMAC7.html)
EP (1) EP3867247B1 (cg-RX-API-DMAC7.html)
JP (1) JP7465868B2 (cg-RX-API-DMAC7.html)
KR (1) KR102854594B1 (cg-RX-API-DMAC7.html)
AR (1) AR116713A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019360017B9 (cg-RX-API-DMAC7.html)
BR (1) BR112021006940A2 (cg-RX-API-DMAC7.html)
DK (1) DK3867247T3 (cg-RX-API-DMAC7.html)
ES (1) ES2988842T3 (cg-RX-API-DMAC7.html)
FI (1) FI3867247T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241318T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068686T2 (cg-RX-API-DMAC7.html)
IL (1) IL282096B2 (cg-RX-API-DMAC7.html)
LT (1) LT3867247T (cg-RX-API-DMAC7.html)
MX (1) MX2021004386A (cg-RX-API-DMAC7.html)
PL (1) PL3867247T3 (cg-RX-API-DMAC7.html)
PT (1) PT3867247T (cg-RX-API-DMAC7.html)
SI (1) SI3867247T1 (cg-RX-API-DMAC7.html)
TW (1) TWI827706B (cg-RX-API-DMAC7.html)
WO (1) WO2020079422A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202101487B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12358901B2 (en) 2018-10-16 2025-07-15 Autifony Therapeutics Limited KV3 modulators
BR112022013339A2 (pt) * 2020-02-06 2022-09-13 Autifony Therapeutics Ltd Moduladores de kv3
EP4384165B1 (en) * 2021-08-09 2025-07-09 Janssen Pharmaceutica NV Monoacylglycerol lipase modulators for use in autism spectrum disorders
CA3226856A1 (en) 2021-08-10 2023-02-16 Autifony Therapeutics Limited Potassium channel modulators
EP4630117A1 (en) 2022-12-06 2025-10-15 Autifony Therapeutics Limited Compounds for the treatment of centra nervous system disorders
WO2026093398A1 (en) 2024-10-29 2026-05-07 Autifony Therapeutics Limited Kv3 modulators for use in the treatment or prophylaxis of amyotrophic lateral sclerosis (als)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012076877A1 (en) 2010-12-06 2012-06-14 Autifony Therapeutics Limited Hydantoin derivatives useful as kv3 inhibitors
WO2013083994A1 (en) 2011-12-06 2013-06-13 Autifony Therapeutics Limited Hydantoin derivatives useful as kv3 inhibitors
WO2013182851A1 (en) 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
WO2017103604A1 (en) 2015-12-16 2017-06-22 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels
WO2018109484A1 (en) 2016-12-16 2018-06-21 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2509961B1 (en) 2009-12-11 2016-03-09 Autifony Therapeutics Limited Imidazolidinedione derivatives
US9193704B2 (en) 2011-06-07 2015-11-24 Autifony Therapeutics Limited Hydantoin derivatives as KV3 inhibitors
GB201209986D0 (en) 2012-06-06 2012-07-18 Autifony Therapeutics Ltd Novel compounds
CN104334547B (zh) 2012-05-22 2017-06-06 奥蒂福尼疗法有限公司 作为kv3抑制剂的三唑类
JP2015517563A (ja) 2012-05-22 2015-06-22 アウトイフオンイ トヘラペウトイクス リミテッド Kv3阻害剤としてのヒダントイン誘導体
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012076877A1 (en) 2010-12-06 2012-06-14 Autifony Therapeutics Limited Hydantoin derivatives useful as kv3 inhibitors
WO2013083994A1 (en) 2011-12-06 2013-06-13 Autifony Therapeutics Limited Hydantoin derivatives useful as kv3 inhibitors
WO2013182851A1 (en) 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
WO2017103604A1 (en) 2015-12-16 2017-06-22 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels
WO2018109484A1 (en) 2016-12-16 2018-06-21 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG, C. et al.,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978),Journal of Medicinal Chemistry,2016年,59(23),pp. 10705-10718

Also Published As

Publication number Publication date
SI3867247T1 (sl) 2024-11-29
FI3867247T3 (fi) 2024-10-30
TWI827706B (zh) 2024-01-01
ES2988842T3 (es) 2024-11-21
HUE068686T2 (hu) 2025-01-28
JP2022505143A (ja) 2022-01-14
TW202035394A (zh) 2020-10-01
WO2020079422A1 (en) 2020-04-23
AU2019360017B2 (en) 2025-03-06
DK3867247T3 (da) 2024-09-16
IL282096A (en) 2021-05-31
KR20210076081A (ko) 2021-06-23
IL282096B1 (en) 2024-03-01
EP3867247A1 (en) 2021-08-25
MX2021004386A (es) 2021-06-04
PL3867247T3 (pl) 2024-12-09
PT3867247T (pt) 2024-09-17
HRP20241318T1 (hr) 2024-12-20
AR116713A1 (es) 2021-06-02
AU2019360017A1 (en) 2021-04-01
EP3867247B1 (en) 2024-07-24
LT3867247T (lt) 2024-11-11
BR112021006940A2 (pt) 2021-07-13
AU2019360017B9 (en) 2025-03-27
KR102854594B1 (ko) 2025-09-02
US20250304564A1 (en) 2025-10-02
IL282096B2 (en) 2024-07-01
ZA202101487B (en) 2024-05-30

Similar Documents

Publication Publication Date Title
KR102854594B1 (ko) 신규한 화합물
CN103596943B (zh) 用作kv3抑制剂的乙内酰脲衍生物
JP7036725B2 (ja) Kv3チャネルのヒダントインモジュレーター
CA2856654C (en) Hydantoin derivatives useful as kv3 inhibitors
WO2018109484A1 (en) Hydantoin modulators of kv3 channels
JP7522203B2 (ja) Kv3モジュレーター
WO2013182850A1 (en) Isobenzofuran- 5 -yl-oxy- (hetero) aryl - imidazolidine - 2, 4 -dione derivatives modulators of kv3 potassium channels for the treatment of cns disorders.
KR20240046748A (ko) 칼륨 채널 조절제
RU2830279C2 (ru) Новые соединения
US12358901B2 (en) KV3 modulators
HK40059039B (en) Novel compounds
HK40059039A (en) Novel compounds
EA049235B1 (ru) Модуляторы kv3
CA3169057C (en) Kv3 modulators
HK40081003B (en) Kv3 modulators
HK40081003A (en) Kv3 modulators
HK40108089A (en) Potassium channel modulators
BR112014013400B1 (pt) Compostos derivados de hidantoína úteis como inibidores de kv3 e seus usos na profilaxia ou tratamento de distúrbios auditivos e esquizofrenia ou no tratamento de síndrome do x frágil

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221014

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221014

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240312

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240401

R150 Certificate of patent or registration of utility model

Ref document number: 7465868

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150